Pages that link to "Q45414505"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials (Q45414505):
Displaying 50 items.
- Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability (Q24628212) (← links)
- An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients (Q26827791) (← links)
- Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor (Q26830730) (← links)
- A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants (Q27675380) (← links)
- Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up (Q28538860) (← links)
- The Global Health Impact Index: Promoting Global Health (Q28551476) (← links)
- HIV-1 Genetic Variability and Clinical Implications (Q30352010) (← links)
- HIV-1 genetic variation and drug resistance development. (Q30354857) (← links)
- New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data (Q30578338) (← links)
- Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR (Q30697730) (← links)
- French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults (Q33775397) (← links)
- HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. (Q33900459) (← links)
- Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors (Q33939069) (← links)
- Single-Tablet Regimens in HIV Therapy (Q33939110) (← links)
- Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks (Q34035045) (← links)
- Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States (Q34181784) (← links)
- Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use. (Q34478840) (← links)
- Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen (Q34536677) (← links)
- Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management (Q35094201) (← links)
- A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. (Q35149475) (← links)
- Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols (Q35288691) (← links)
- Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand (Q35530299) (← links)
- Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy (Q35907952) (← links)
- Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials (Q36276597) (← links)
- Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants (Q36583683) (← links)
- Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir (Q36603434) (← links)
- A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus (Q36692572) (← links)
- Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection (Q36958229) (← links)
- Next-generation oral preexposure prophylaxis: beyond tenofovir (Q37067126) (← links)
- Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines (Q37225380) (← links)
- Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. (Q37263531) (← links)
- Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. (Q37410986) (← links)
- Are subtype differences important in HIV drug resistance? (Q37633109) (← links)
- Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials. (Q37639881) (← links)
- Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland. (Q37710424) (← links)
- Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement (Q38022319) (← links)
- Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF. (Q38030981) (← links)
- Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation (Q38040137) (← links)
- Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication (Q38060236) (← links)
- Does once-daily etravirine have a role in the management of HIV-1 infection? (Q38082671) (← links)
- Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods (Q38086335) (← links)
- Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection (Q38263470) (← links)
- Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis (Q38272654) (← links)
- Backbones versus core agents in initial ART regimens: one game, two players. (Q38690825) (← links)
- Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients (Q39366403) (← links)
- Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials (Q39515202) (← links)
- Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. (Q39813922) (← links)
- Moving forward with treatment options for HIV-infected children. (Q40063042) (← links)
- Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study (Q40132756) (← links)
- Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir (Q40544015) (← links)